Blockchain Registration Transaction Record

CNS Pharmaceuticals Releases Q2 2024 Financial Results and Clinical Development Progress

CNS Pharmaceuticals releases Q2 2024 financial results and discusses clinical development progress of Berubicin and TPI 287 for the treatment of brain malignancies.

CNS Pharmaceuticals Releases Q2 2024 Financial Results and Clinical Development Progress

This news matters as it provides an update on CNS Pharmaceuticals' financial performance and the progress of its lead programs for the treatment of brain and CNS cancers. Investors, healthcare professionals, and individuals affected by brain malignancies should pay attention to the potential impact of the company's clinical developments on future treatment options.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xe127f070eb6429624656ea7a98aa9436c7ac055f1adb6f8f6eee680e0ce32435
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintpinkff0X-9a152e7ea2cf2eeaf9cb450c9d12cb3c